Predictive Diagnostics

Global Market Trajectory & Analytics

MCP-7843

EXECUTIVE ENGAGEMENTS

POOL

4302
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

774
Interactions with Platform & by Email

PARTICIPANTS

129
Unique # Participated

VALIDATIONS

37
Responses Validated*

COMPANIES

47
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

32

PAGES

109

EDITION

19

PRICE

USD 5600

CODE

MCP-7843


COMPETITIVE METRICS

COMPANY

D S N T

% *

23andMe, Inc.

Agilent Technologies, Inc.

Almac Group

AlphaBiomics

Ambry Genetics

Asper Biogene LLC

Asuragen, Inc.

Athena Diagnostics, Inc.

ATS GeneTech Pvt., Ltd.

Attain It S.R.L.

*Login to Participate & View Data Stacks
View 47 Companies...

SUBMIT
Note: Best viewed in Landscape Mode
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Predictive Diagnostics estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$2.5 Billion by 2027, growing at a CAGR of 9.9% over the period 2020-2027.
The Predictive Diagnostics market in the U.S. is estimated at US$376.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$424.6 Million by the year 2027 trailing a CAGR of 9.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.1% and 8.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8% CAGR.

SELECT PLAYERS

Abbott Molecular; Almac Group Ltd.; Ambry Genetics Corp.; BioGenex; Epistem Ltd.; Epistem Ltd.; MDxHEALTH Inc.; Myriad Genetics Inc.; OPKO Health, Inc.; Prometheus Laboratories Inc.; QIAGEN N.V.

SEGMENTS

» Segment (Predictive Diagnostics)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
A Curtain Raiser
Recent Market Activity
Predictive Diagnostics - A Key Segment of Genetic Testing
Outlook for Predictive Diagnostics Market
Growing Popularity of Multi-gene Panels in Clinical Cancer Genetics
Clinical Characteristics of Moderate-High Penetrance Genes Other than BRCA1/2
Challenges Associated with Multigene-Panel Testing
Next-Generation Sequencing - A Giant Leap in Genome Sequencing
Genes Included in NGS Panels
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
Abbott Molecular (USA)
Almac Group Ltd. (Ireland)
Ambry Genetics Corporation (USA)
BioGenex (USA)
Epistem Ltd. (UK)
F. Hoffmann-La Roche Ltd. (Switzerland)
Genomic Health, Inc. (USA)
MDxHEALTH, Inc. (USA)
Myriad Genetics, Inc. (USA)
OPKO Health, Inc. (USA)
Prometheus Laboratories Inc. (USA)
Proteomics International Laboratories Ltd (Australia)
QIAGEN N.V. (The Netherlands)
3. MARKET TRENDS & DRIVERS
Rising Incidence and Prevalence of CDDs: A Major Growth Driver
Increasing Cancer Disease Burden Drives the Demand for Predictive Diagnostics
Incidence of Neurodegenerative Diseases Increasing
Alzheimer’s Disease
Huntington’s Disease
Parkinson’s Disease
Ballooning Global Population Offers Significant Growth Opportunities
Predictive Diagnostics Enable Higher Life Expectancy
Widening of Insurance Coverage for Hereditary Cancer Testing
Discovery of Novel Biomarkers - Crucial to Predictive Diagnostics
Genomic Research Remains Confined to Fundamental Research
Unresolved Issues Hamper Widespread Implementation of Genetic Testing for Monogenetic Disease
Dearth of Genetic Counselors - A Major Hurdle for the Predictive Genetic Testing
Framework for Validation, Regulation, and Ethical Issues - The Need of the Hour
Prospects for Predictive Genetic Diagnostics Grow Brighter
Predictive Diagnostics - Crucial for Breast Cancer Management
Inherited Breast Cancer - An Important End-use Market for Predictive Diagnostics
Oncology: A Key Growth Driver for Predictive Diagnostics
Genes and Associated Cancers/Tumors
Increasing Incidence of Colorectal Cancer in <50 Age Group: A Business Case for Predictive Diagnostics
Growing Number of Colorectal Cancer Risk Population with Lynch Syndrome
Launch of PromarkerD: Hope for Early Diagnosis of Diabetic Kidney Disease
What is PromarkerD?
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Predictive Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Predictive Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Predictive Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Predictive Diagnostics by Segment - Predictive Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Predictive Diagnostics by Segment - Predictive Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
CANADA
Canada Current & Future Analysis for Predictive Diagnostics by Segment - Predictive Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Predictive Diagnostics by Segment - Predictive Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
JAPAN
Japan Current & Future Analysis for Predictive Diagnostics by Segment - Predictive Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Predictive Diagnostics by Segment - Predictive Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
CHINA
China Current & Future Analysis for Predictive Diagnostics by Segment - Predictive Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Predictive Diagnostics by Segment - Predictive Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
EUROPE
Europe Current & Future Analysis for Predictive Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Predictive Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Predictive Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Predictive Diagnostics by Segment - Predictive Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Predictive Diagnostics by Segment - Predictive Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
GERMANY
Germany Current & Future Analysis for Predictive Diagnostics by Segment - Predictive Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Predictive Diagnostics by Segment - Predictive Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
ITALY
Italy Current & Future Analysis for Predictive Diagnostics by Segment - Predictive Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Predictive Diagnostics by Segment - Predictive Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UNITED KINGDOM
UK Current & Future Analysis for Predictive Diagnostics by Segment - Predictive Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Predictive Diagnostics by Segment - Predictive Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
REST OF EUROPE
Rest of Europe Current & Future Analysis for Predictive Diagnostics by Segment - Predictive Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Predictive Diagnostics by Segment - Predictive Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Predictive Diagnostics by Segment - Predictive Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Predictive Diagnostics by Segment - Predictive Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
REST OF WORLD
Rest of World Current & Future Analysis for Predictive Diagnostics by Segment - Predictive Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Predictive Diagnostics by Segment - Predictive Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Total Companies Profiled: 47

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com